s
Dragonfly Therapeutics, Inc. Announces Clinical Collaboration to Evaluate DF9001, an EGFR targeting TriNKET®, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors
21-05-2024, 13:02
DF9001 is currently being evaluated as a monotherapy for the treatment of Non-Small Cell Lung Cancer, Renal Cell Carcinoma and Head and Neck Squamous Cell Carcinoma. The clinical trial collaboration will focus on evaluating the investigational combination in second line Renal Cell Carcinoma and second line Head and Neck Squamous Cell Carcinoma. WALTHAM, Mass., May 21, […] L'articolo Dragonfly Therapeutics, Inc. Announces Clinical Collaboration to Evaluate DF9001, an EGFR targeting TriNKET®, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors proviene da La Ragione.
CONTINUA A LEGGERE
14
0
0
Guarda anche
La Ragione
01:43
Tripletta Thuram, Inter batte 3-2 il Torino
La Ragione
Ieri, 21:43
Manovra, Tajani “Extraprofitto incomprensibile, concetto extraterrestre”
La Ragione
Ieri, 19:43
Confesercenti “Tetti agli affitti per le attività di prossimità”
La Ragione
Ieri, 19:43
Scontri a Roma tra i manifestanti pro Palestina e le forze dell’ordine
La Ragione
Ieri, 18:52
Alimentazione, esperti: “Con esercizio fisico pilastri longevità sana”
La Ragione
Ieri, 18:12